Angela Mastronuzzi: The current landscape of CAR T-cell therapy for CNS tumors
Authors: Giada Del Baldo, Andreac Carai, Angela Mastronuzzi.
” ‘Review: Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them’ published with Current Opinion in Oncology of Wolters Kluwer.
This review aims to explore the current landscape of CAR T-cell therapy for central nervous system (CNS) tumors, highlighting recent advancements and addressing challenges in achieving therapeutic efficacy.
Key Points:
- Brain tumors are still associated to high mortality and morbidity and CAR T-cells could be an effective strategy to improve outcome
- CART-cells in brain tumors possesses many challenges that need to be overcome, including immunosuppressive microenvironment, heterogeneous antigens, CAR T-cell exhaustion, cell trafficking and neurotoxicity.
- To date there are about 40 clinical trials available to treat pediatric and adult patients affected by refractory or recurrent CNS tumors and some data have recently been published.
- Both preclinical and clinical data have shown that locoregional delivery of CART cells is well tolerated.”
Angela Mastronuzzi is pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023